[1] SRINIVAS R. KASIBHATLA. Rationally Designed High-Affinity 2-Amino-6-halopurine Heat Shock Protein 90 Inhibitors That Exhibit Potent Antitumor Activity[J]. Journal of Medicinal Chemistry, 2007, 50 12: 2767-2778. DOI:
10.1021/jm050752+[2] KAREN LUNDGREN. BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90.[J]. Molecular Cancer Therapeutics, 2009: 921-929. DOI:
10.1158/1535-7163.mct-08-0758[3] BORIS BÖLL. Heat shock protein 90 inhibitor BIIB021 (CNF2024) depletes NF-kappaB and sensitizes Hodgkin’s lymphoma cells for natural killer cell-mediated cytotoxicity.[J]. Clinical Cancer Research, 2009: 5108-5116. DOI:
10.1158/1078-0432.ccr-09-0213[4] HONG ZHANG. BIIB021, a synthetic Hsp90 inhibitor, has broad application against tumors with acquired multidrug resistance[J]. International Journal of Cancer, 2009, 126 5: 1226-1234. DOI:
10.1002/ijc.24825[5] XIN-TONG WANG . BIIB021, a novel Hsp90 inhibitor, sensitizes esophageal squamous cell carcinoma to radiation[J]. Biochemical and biophysical research communications, 2014, 452 4: Pages 945-950. DOI:
10.1016/j.bbrc.2014.09.026